UBS Group’s Akari Therapeutics AKTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-821
| Closed | -$9.5K | – | 10431 |
|
|
2025
Q4 | $9.5K | Buy |
821
+819
| +40,950% | +$19K | ﹤0.01% | 8281 |
|
|
2025
Q3 | $61 | Sell |
2
-52
| -96% | -$2.02K | ﹤0.01% | 9993 |
|
|
2025
Q2 | $2.52K | Buy |
+54
| New | +$2.72K | ﹤0.01% | 9446 |
|
|
2025
Q1 | – | Sell |
-5
| Closed | -$237 | – | 10182 |
|
|
2024
Q4 | $237 | Buy |
+5
| New | +$376 | ﹤0.01% | 9555 |
|
|
2024
Q3 | – | Sell |
-399
| Closed | -$43.1K | – | 9461 |
|
|
2024
Q2 | $43.1K | Buy |
+399
| New | +$29.4K | ﹤0.01% | 6813 |
|
|
2023
Q3 | – | Sell |
-31
| Closed | -$4.16K | – | 9413 |
|
|
2023
Q2 | $4.16K | Buy |
+31
| New | +$4.48K | ﹤0.01% | 7562 |
|
|
2022
Q4 | – | Sell |
-1
| Closed | – | – | 10686 |
|
|
2022
Q3 | $0 | Sell |
1
-3
| -75% | -$2.47K | ﹤0.01% | 10281 |
|
|
2022
Q2 | $3K | Buy |
+4
| New | +$3.55K | ﹤0.01% | 9272 |
|
|
2021
Q4 | – | Sell |
-1
| Closed | -$2K | – | 10226 |
|
|
2021
Q3 | $2K | Buy |
+1
| New | +$1.36K | ﹤0.01% | 8925 |
|
|
2021
Q1 | – | Sell |
-2
| Closed | -$3K | – | 8946 |
|
|
2020
Q4 | $3K | Buy |
+2
| New | +$2.77K | ﹤0.01% | 7979 |
|
|
2020
Q3 | – | Sell |
-1
| Closed | -$1K | – | 7943 |
|
|
2020
Q2 | $1K | Sell |
1
-6
| -86% | -$9.14K | ﹤0.01% | 7733 |
|
|
2020
Q1 | $8K | Buy |
+7
| New | +$9.75K | ﹤0.01% | 7062 |
|
|
2019
Q4 | – | Sell |
-3
| Closed | -$4K | – | 8083 |
|
|
2019
Q3 | $4K | Buy |
+3
| New | +$4.59K | ﹤0.01% | 7530 |
|
|
2019
Q2 | – | Sell |
-2
| Closed | -$4K | – | 7829 |
|
|
2019
Q1 | $4K | Sell |
2
-13
| -87% | -$24.8K | ﹤0.01% | 7242 |
|
|
2018
Q4 | $19K | Buy |
+15
| New | +$22K | ﹤0.01% | 6818 |
|
|
2018
Q3 | – | Sell |
-4
| Closed | -$5K | – | 7946 |
|
|
2018
Q2 | $5K | Buy |
+4
| New | +$6.28K | ﹤0.01% | 7454 |
|
|
2018
Q1 | – | Hold |
0
| – | – | – | 7775 |
|
|
2017
Q4 | – | Sell |
-3
| Closed | -$11.6K | – | 7816 |
|
|
2017
Q3 | $13K | Hold |
3
| – | – | ﹤0.01% | 6726 |
|
|
2017
Q2 | $13K | Sell |
3
-3
| -50% | -$23.7K | ﹤0.01% | 6592 |
|
|
2017
Q1 | $50K | Sell |
6
-21
| -78% | -$118K | ﹤0.01% | 5522 |
|
|
2016
Q4 | $152K | Sell |
27
-1
| -4% | -$6.46K | ﹤0.01% | 4980 |
|
|
2016
Q3 | $189K | Sell |
28
-4
| -13% | -$31.2K | ﹤0.01% | 4584 |
|
|
2016
Q2 | $345K | Buy |
32
+30
| +1,500% | +$387K | ﹤0.01% | 4172 |
|
|
2016
Q1 | $18K | Buy |
2
+1
| +100% | +$10.4K | ﹤0.01% | 6277 |
|
|
2015
Q4 | $10K | Hold |
1
| – | – | ﹤0.01% | 7266 |
|
|
2015
Q3 | $21K | Buy |
+1
| New | +$11.8K | ﹤0.01% | 6631 |
|
|
2015
Q2 | – | Hold |
0
| – | – | – | 8167 |
|
|
2015
Q1 | – | Hold |
0
| – | – | – | 8550 |
|
Other funds holding AKTX
AC
CAM
IA
SS
TC
UBS Group's AKTX Position: Q1 2026 in Review
UBS Group sold out of Akari Therapeutics (AKTX) in Q1 2026, closing a stake of 821 shares — an estimated $9.5K sold.
UBS Group first reported a position in AKTX in Q3 2015 and held it in 25 quarters. The position peaked at $345K in Q2 2016. 6 funds tracked by Wall St. Rank hold AKTX as of Q1 2026.
- UBS Group reported no remaining Akari Therapeutics position as of Q1 2026 after selling out during the quarter.
- UBS Group sold 821 Akari Therapeutics shares in Q1 2026, an estimated $9.5K.
- UBS Group first reported a position in Akari Therapeutics in Q3 2015 and held it in 25 quarters.
- UBS Group's Akari Therapeutics position peaked at $345K in Q2 2016.
- 6 funds tracked by Wall St. Rank held Akari Therapeutics as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.